When is CLEW Medical the better choice?

It publishes the operating characteristics of its cleared models in a public regulatory document, so sensitivity and specificity are readable rather than asserted. The cleared indications carry an explicit adjunctive constraint stating predictions are for reference only, which bounds what a hospital may build on them. It produced the first direct measurement of this category's defining failure, comparing model output against what clinicians actually did, published in a peer reviewed journal.

When is Luminare the better choice?

Its founding argument is that prediction was never the constraint, and it builds around intervention, bundle completion and workflow instead, which is where screening programmes actually fail. The commercial disclosure is the best in this category and it publishes a genuine implementation ladder with timelines, which almost nothing else here does. The mechanism is described plainly enough that you can tell exactly what the product does, which places it at the transparent end of a category full of proprietary scores.

CLEW Medical vs Luminare

Last VerifiedAugust 4, 2026

Verdict

Two vendors who both think this category is measuring the wrong thing, for different reasons. CLEW measured it directly, publishing the operating characteristics of its cleared models in a public regulatory document and then producing the first study comparing model output against what clinicians actually did, which is the failure everyone else assumes away. Luminare argues the prediction was never the problem: hospitals already know which patients are at risk and fail at the bundle and the workflow that follow, and it publishes the best commercial disclosure and implementation ladder in the category. If your screening score is already firing into a ward that ignores it, Luminare is aimed at your real failure and is the less evidenced of the two. CLEW is the regulated instrument with published numbers behind it.

Select CLEW Medical if

It publishes the operating characteristics of its cleared models in a public regulatory document, so sensitivity and specificity are readable rather than asserted.
The cleared indications carry an explicit adjunctive constraint stating predictions are for reference only, which bounds what a hospital may build on them.
It produced the first direct measurement of this category's defining failure, comparing model output against what clinicians actually did, published in a peer reviewed journal.

Select Luminare if

Its founding argument is that prediction was never the constraint, and it builds around intervention, bundle completion and workflow instead, which is where screening programmes actually fail.
The commercial disclosure is the best in this category and it publishes a genuine implementation ladder with timelines, which almost nothing else here does.
The mechanism is described plainly enough that you can tell exactly what the product does, which places it at the transparent end of a category full of proprietary scores.

Attribute Matrix

Side by Side

Axis	C CLEW Medical	L Luminare
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.

AITRICS VitalCare vs CLEW Medical→CLEW Medical vs Etiometry→Epic Sepsis Model vs Luminare→Healthplus.ai vs Luminare→

Disclosure

The two are not equivalent objects: one is a cleared device with published operating characteristics and an adjunctive constraint, the other is not cleared and states it operates without clearance on the basis of the claims it makes. Luminare's central argument is supported by a review article its own chief executive co authored, which is a stated position rather than independent evidence, and no controlled outcome evaluation of the product itself was located. Neither publishes subgroup performance or calibration analysis. Neither publishes an alert burden figure per patient day, which determines whether either survives contact with a working ward.